FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-02										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							•											
1. Name and Address of Reporting Person* ADAMIS ANTHONY P					Ey	2. Issuer Name <b>and</b> Ticker or Trading Symbol  EyePoint Pharmaceuticals, Inc. [ EYPT ]								neck all appli	cable) or	Perso	erson(s) to Issuer	
(Last)	(F	irst)	(Middle)				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2024								Officer (give title below)		Other (spec below)	
C/O EYEPOINT PHARMACEUTICALS, INC.				4. I1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. 1	6. Individual or Joint/Group Filing (Check Applicable					
480 PLE	ASANT S	ΓREET											Lin		filed by One	Report	ting Persor	n
(Street)														Form Perso	filed by More	e than C	One Repor	ting
WATERT	TOWN M	MA 02472		Rı	Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - Nor	n-Deriv	ative	Se	curiti	es Ac	quired	Dis	posed (	of, or Be	neficia	lly Owne	d			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da						Execution Da			e, Transaction D Code (Instr. 5			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)		Benefic	es ially Following	6. Own Form: I (D) or I (I) (Inst	Direct c ndirect E tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			111501.4)
Common Stock 06/23/2				3/2024	/2024		M		2,000 A		\$0.0	0 4,	000	I	D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		expiration Pate	Title	Amount or Number of Shares					
Restricted Stock Units	\$0.00	06/23/2024			M			2,000	(1)		(1)	Common Stock	2,000	\$0.00	2,000		D	

## **Explanation of Responses:**

1. The restricted stock units vests in three ratable annual installments beginning June 23, 2023.

## Remarks:

/s/ Ron Honig, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person Date

06/25/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.